Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice

Henry S. Friedman, Stephen T. Keir, Peter J. Houghton, Amy A. Lawless, Darell D. Bigner, Stephen J. Waters

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Purpose: This study was conducted to define the activity of irofulven in the treatment of a series of xenografts derived from human glioblastoma multiforme growing subcutaneously and intracranially in athymic nude mice. Methods: Athymic mice bearing subcutaneous or intracranial tumors were treated with irofulven at a 10% lethal dose with responses compared to tumor-bearing mice treated with drug vehicle. Results: Irofulven was active against all tumor lines tested with growth delays ranging from 5.6 to 81.6 days (all values statistically significant, P ≤ 0.001). Irofulven also produced a statistically significant (P ≤ 0.001) increase in the median survival of mice bearing D-456 intracranial xenografts with a 162% increase in median survival. Conclusions: Irofulven is active in a spectrum of human glioblastoma multiforme-derived xenografts and evaluation in patients with this neoplasm is warranted.

Original languageEnglish (US)
Pages (from-to)413-416
Number of pages4
JournalCancer chemotherapy and pharmacology
Volume48
Issue number5
DOIs
StatePublished - 2001
Externally publishedYes

Keywords

  • CNS tumors
  • Glioblastoma multiforme
  • Irofulven
  • Nude mice
  • Xenografts

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice'. Together they form a unique fingerprint.

Cite this